BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Jun 21, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

NKTR-102: Phase II data

In an open-label Phase II trial in 68 patients treated with NKTR-102 dosed either every 2 or 3 weeks, both dosing regimens led to a 41% confirmed and unconfirmed ORR using GCIG criteria. Confirmed ORRs using GCIG criteria were 29% and 38% for NKTR-102 dosed every 2...

Read the full 211 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >